Efficacy of topical tofacitinib, a Janus kinase inhibitor, in the treatment of plaque psoriasis

被引：6
|
作者：
Bagherani, Nooshin [1 ]
Smoller, Bruce R. [2 ]
机构：
[1] Dr Nooshin Bagherans Off, Khoramshahr, Khuzestan Provi, Iran
[2] Univ Rochester, Sch Med & Dent, Dept Dermatol, Dept Pathol, Rochester, NY 14642 USA
来源：
DERMATOLOGIC THERAPY | 2017年 / 30卷 / 03期
关键词：
psoriasis; tofacitinib; treatment; CLINICAL-TRIAL;
D O I：
10.1111/dth.12467
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
    Ports, W. C.
    Khan, S.
    Lan, S.
    Lamba, M.
    Bolduc, C.
    Bissonnette, R.
    Papp, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2013, 169 (01) : 137 - 145
  • [2] Efficacy and safety of topical janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis: Results of a phase IIA randomized clinical trial
    Ports, William
    Bolduc, Chantal
    Papp, Kim
    Lamba, Manisha
    Bissonnette, Robert
    Khan, Shahbaz
    Lan, Shuping
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB199 - AB199
  • [3] Topical Tofacitinib: A Janus Kinase Inhibitor for the Treatment of Vitiligo in an Adolescent Patient
    Berbert Ferreira, Sineida
    Berbert Ferreira, Rachel
    Neves Neto, Afonso Cesar
    Assef, Silvana Martins Caparroz
    Scheinberg, Morton
    CASE REPORTS IN DERMATOLOGY, 2021, 13 (01): : 190 - 194
  • [4] Treatment of halo naevus with the topical Janus kinase inhibitor tofacitinib 1.5%
    Hu, W. T.
    Lin, F. Q.
    Xu, A. E.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2018, 43 (08) : 935 - 937
  • [5] Tofacitinib: a new oral Janus kinase inhibitor for psoriasis
    Gimenez-Arnau, A. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (01) : 13 - 14
  • [6] Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, on Clinical Signs of Moderate-to-Severe Plaque Psoriasis in Different Body Regions
    Menter, Alan
    Papp, Kim A.
    Tan, Huaming
    Tyring, Steve
    Wolk, Robert
    Buonanno, Marjorie
    JOURNAL OF DRUGS IN DERMATOLOGY, 2014, 13 (03) : 252 - 256
  • [7] Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis
    Tan, H.
    Gupta, P.
    Harness, J.
    Wolk, R.
    Chapel, S.
    Menter, A.
    Strober, B.
    Langley, R. G.
    Krishnaswami, S.
    Papp, K. A.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2013, 2 (05):
  • [8] Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial
    Papp, Kim A.
    Bissonnette, Robert
    Gooderham, Melinda
    Feldman, Steven R.
    Iversen, Lars
    Soung, Jennifer
    Draelos, Zoe
    Mamolo, Carla
    Purohit, Vivek
    Wang, Cunshan
    Ports, William C.
    BMC DERMATOLOGY, 2016, 16
  • [9] Antipruritic Effects of Janus Kinase Inhibitor Tofacitinib in a Mouse Model of Psoriasis
    Hashimoto, Takashi
    Sakai, Kent
    Sanders, Kristen M.
    Yosipovitch, Gil
    Akiyama, Tasuku
    ACTA DERMATO-VENEREOLOGICA, 2019, 99 (03) : 298 - 303
  • [10] Safety of tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: integrated data analysis from the global clinical trials
    Langley, Richard G. B.
    Cohen, Arnon D.
    Foley, Peter
    Griffiths, Christopher E. M.
    Lebwohls, Mark
    Leonardi, Craig
    Winthrop, Kevin
    Proulx, James
    Rottinghaus, Scott T.
    Wolk, Robert
    Thompson, John R.
    Tatulych, Svitlana
    Mallbris, Lotus
    Swanson, Robert
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S9 - S9
12345